glp 1 for crohn's disease In a patient with moderate disease, is it safe to start a GLP‑1 receptor agonist, and what dosing and monitoring steps are recommended? Frontiers | GLP-1 receptor agonists

we are faithfully looking forward to cooperating with you

According to a 2024 study by Duo Do et al., reported that the use of a once-weekly GLP-1 receptor agonist was independently linked to a 30.5% higher prevalence of elevated residual gastric content on preprocedural gastric ultrasonography, which is a significant risk factor for aspiration during anesthesia

Novo Nordisk offers savings programs for Wegovy, and Eli Lilly has programs for Zepbound

Not all compounding pharmacies are made the same, says Janice Jin Hwang, a clinician and endocrinologist at the University of North Carolina at Chapel Hill

Interestingly, these pharmacological concentrations align closely with peak levels of endogenous GLP-1 observed during intense physiological stimulation [120, 121]